Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability

Clin Genitourin Cancer. 2022 Apr;20(2):183-188. doi: 10.1016/j.clgc.2021.11.015. Epub 2021 Dec 24.

¹ Department of Oncology, Hospital Sírio-Libanês, São Paulo, Brazil. Electronic address: alineblara@yahoo.com.br.
² Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD.
³ Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD; Department of Oncology, Hospital Moinhos de Vento, Porto Alegre, Brazil.
⁴ Department of Oncology, Hospital Sírio-Libanês, São Paulo, Brazil.
⁵ Department of nuclear medicine, Hospital Sírio-Libanês, São Paulo, Brazil.
⁶ Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
⁷ Department of Medicine, Division of Hematology/Oncology and Transplantation, University of Minnesota, Minneapolis, MN.

No abstract available

Keywords: Biomarkers; Checkpoint inhibitors; bipolar androgen therapy; castration-resistant prostate cancer; personalized therapy; radium-223.

Publication types